CFT7455 is an anti-cancer agent showing high affinity to the cereblon E3 ligase with a Kd of 0.9 nM. CFT7455 is an orally active degrader of zinc finger transcription factors Ikaros (IKZF1), and Aiolos (IKZF3).

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:20 mg/mL (42.60 mM)

CFT7455 enables potent cell growth inhibition in both previously untreated NCIH929 multiple myeloma cell lines with an IC50 of 0.071 nM and NCIH929 cells made resistant to both lenalidomide and pomalidomide with an IC50 of 2.3 nM. CFT7455 promotes the degradation of >75% of steady state IKZF1 in multiple myeloma cells within 1.5 hours at 0.3 nM[1].

In mouse xenograft tumor models, CFT7455 (3 μg/kg-100 μg/kg) led to durable tumor regression and demonstrates dose-dependent efficacy[1].